Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients

Authors :: Helle Wulf-Johansson
Bruce E. Miller
Jørgen Vestbo
Anders Schlosser
Ruth Tal-Singer
Grith Lykke Sørensen
Sofie Lock Johansson
Ingrid Louise Titlestad
Uffe Holmskov
Source :: ERJ Open Research, Johansson, S L, Wulf-Johansson, H, Schlosser, A, Titlestad, I L, Miller, B, Tal-Singer, R, Holmskov, U, Vestbo, J & Sørensen, G L 2019, ' Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients ', ERJ Open Research, vol. 5, no. 2, 00021-2019 . https://doi.org/10.1183/23120541.00021-2019, ERJ Open Research, Vol 5, Iss 2 (2019)
Publication Year :: 2019
Publisher :: European Respiratory Society (ERS), 2019.
Abstract: Chronic obstructive pulmonary disease (COPD) is characterised by chronic airflow limitation and inflammation of the airways and lung parenchyma. COPD is associated with many comorbidities, especially cardiovascular disease (CVD), which share similar risk factors with COPD [1].<br />Circulating MFAP4 is a relevant biomarker to identify COPD patients at risk of death and cardiovascular comorbidity after smoking cessation http://ow.ly/6vnL30o8t1g

Tools